期刊文献+
共找到81篇文章
< 1 2 5 >
每页显示 20 50 100
Tunable and sustained-release characteristics of venlafaxine hydrochloride from chitosan–carbomer matrix tablets based on in situ formed polyelectrolyte complex film coating 被引量:1
1
作者 Xiaofei Zhang Xiangqin Gu +2 位作者 Xiaodan Wang Huimin Wang Shirui Mao 《Asian Journal of Pharmaceutical Sciences》 SCIE CAS 2018年第6期566-574,共9页
The objective of this study is to design sustained-release tablets using matrix technology, which can well control the release of highly water-soluble drugs with good system robustness and simple preparation process. ... The objective of this study is to design sustained-release tablets using matrix technology, which can well control the release of highly water-soluble drugs with good system robustness and simple preparation process. Taking venlafaxine hydrochloride(VH) as a drug model, the feasibility of using chitosan(CS), carbomer(CBM) combination system to achieve this goal was studied. Formulation and process variables influencing drug release from CS–CBM matrix tablets were investigated. It was found that CS–CBM combination system weakened the potential influence of CS, CBM material properties and gastric emptying time on drug release profile. Demonstrated by direct observation, differential scanning calorimetry(DSC) and Fourier transform infrared spectroscopy(FTIR), in situ self-assembled polyelectrolyte complex(PEC) film was formed on the tablet surface during gastrointestinal tract transition, which contributed to the tunable and robust control of drug release. The sustained drug release behavior was further demonstrated in vivo in Beagle dogs, with level A in vitro and in vivo correlation(IVIVC) established successfully. In conclusion, CS–CBM matrix tablets are promising system to tune and control the release of highly water-soluble drugs with good system robustness. 展开更多
关键词 venlafaxine HYDROCHLORIDE POLYELECTROLYTE complex sustained-release Robustness PHARMACOKINETIC
下载PDF
Pharmacokinetics of nifedipine sustained-release tablets in healthy Chinese volunteers 被引量:3
2
作者 武静 王本杰 +2 位作者 魏春敏 卜凡龙 郭瑞臣 《Journal of Chinese Pharmaceutical Sciences》 CAS 2007年第3期192-196,共5页
Aim To establish a LC-MS method for determining the concentration of nifedipine in human plasma and to evaluate the pharmacokinetic characteristics of nifedipine sustained-release tablets. Methods A XB-C18 (5 μm, 4.... Aim To establish a LC-MS method for determining the concentration of nifedipine in human plasma and to evaluate the pharmacokinetic characteristics of nifedipine sustained-release tablets. Methods A XB-C18 (5 μm, 4.6 mm ×150 mm) column and a mobile phase of methanol: 0.01 mol·L^-1ammonium acetate (60:40, V/V) were used to separate nifedipine, the detections was accuracy under atmosperic pressure electronic spray ionization (AP-ESI) mode and ion mass spectrum (m/z) of 314.9 [M+H]^+ for nifedipine, and 320.8 [M+H]^+ for lorazepam (Internal Standard, IS). Results The linear range of nifedipine was 0.3 - 80 ng·mL^-1 ( r = 0.9997), and the limit of quantitation (LOQ) was 0.3 ng·mL^-1. The nifedipine pharmacokinetic parameters after a single dose of 20 mg nifedipine sustained-release tablets test (T) or reference (R) were as the followings, t1/2 (6.73 ± 2.00) h and (7.04 ± 2.18) h, Tmax (4.28 ± 0.70) h and (4.48 ± 0.70) h, Cmax(39.66 ± 10.58) ng·mL^-1 and (40.19 ± 10.97) ng·mL^-1, AUC0-36 (391.63 ± 108.55) ng·mL^-1·h and (387.57 ± 121.51) ng·mL^-1·h, and AUC0-∞ (408.28 ± 121.16) ng·mL^-1·h and (406.15 ± 133.13) ng·mL^-1·h. The relative bioavailability of nifedipine sustained-release tablets (test) was (103.02 ± 13.93) %. Conclusion LC-MS method for the determination of concentrations of nifedipine in human plasma was sensitive and accurate, and could be used in nifedipine bioavailability and pharmacokinetic studies. 展开更多
关键词 Nifedipine sustained-release tablets LC-MS PHARMACOKINETICS BIOEQUIVALENCE
下载PDF
Preparation and <i>in Vitro</i>Drug Release Evaluation of Once-Daily Metformin Hydrochloride Sustained-Release Tablets 被引量:1
3
作者 Ling Zhao Yumeng Wei +4 位作者 Yong Mei Li Yang Yuan You Xufeng Yang Yanhong Jiang 《Pharmacology & Pharmacy》 2012年第4期468-473,共6页
The objective of this study was to develop once-daily metformin hydrochloride sustained-release tablets (MHSRT) and evaluate their in vitro release behavior. MHSRT were prepared by the film coating method. The in vitr... The objective of this study was to develop once-daily metformin hydrochloride sustained-release tablets (MHSRT) and evaluate their in vitro release behavior. MHSRT were prepared by the film coating method. The in vitro drug release rate of MHSRT and the commercial tablets Fortamet? made in the United States of America in water was fitted with zero order kinetic equation, and Ritger-Peppas kinetic equation in 0.1 M HCl and pH 6.8-phosphate buffer, respectively. The similarity factor f2 values of MHSRT in three different dissolution medium were 82, 80 and 74, respectively in comparison with imported Fortamet?, which were all greater than 50. The results of storage-stability showed that MHSRT were stable for at least 6 months under stress condition (40℃ ± 2℃, RH 75% ± 5%). Therefore, in this study, MHSRT were successfully prepared using optimized formulation technologies that meet mass produce. The in vitro release behavior of MHSRT was almost similar to that of imported Fortamet?. 展开更多
关键词 sustained-release tablets METFORMIN HYDROCHLORIDE In Vitro Release Rate Similarity Factor Kinetic Model
下载PDF
Pharmacokinetic Study on Lovastatin Sustained-release Tablet and Sustained-release Capsule in Begal Dogs
4
作者 付琳 代宗顺 +1 位作者 侯淑贤 万元胜 《Journal of Huazhong University of Science and Technology(Medical Sciences)》 SCIE CAS 2004年第2期116-119,共4页
This study pharmacokinetically examined the lovastatin sustained-release tablet and sustained-release capsule in Beagle dogs. An reversed-phase HPLC method was established for the determination of lovastatin in Beagl... This study pharmacokinetically examined the lovastatin sustained-release tablet and sustained-release capsule in Beagle dogs. An reversed-phase HPLC method was established for the determination of lovastatin in Beagle dog plasma. Pharmacokinetic findings were compared among three preparation(lovastatin sustained-release tablet,T p; sustained-release capsule,T J and conventional capsule). Our results showed that the pharmacokinetic parameters in 6 dogs after single-dose oral administration of three perparations were calculated. T max, C max and MRT revealed significant difference (P<0.05). Relative bioavailability was 111.5±16.9 % (T P) and 110.4%±9.6 % (T J). The pharmacokinetic parameters in the 6 dogs after multiple-dose oral administration of three perparations, T max, C max MRT and DF had significant difference (P<0.05); C av , C min and AUC 0-24 h displayed no significant difference (P>0.05). It is concluded that the lovastatin sustained-release tablet and sustained-release capsule are able to maintain a sustained-release for 24 h. 展开更多
关键词 LOVASTATIN sustained-release tablets sustained-release capsules PHARMACOKINETIC SINGLE-DOSE MULTIPLE-DOSE
下载PDF
Preparation and evaluation of sustained-release azithromycin tablets in vitro and in vivo
5
作者 Le Sun Weixiang Zhang +1 位作者 Xiaohong Liu Jin Sun 《Asian Journal of Pharmaceutical Sciences》 SCIE CAS 2014年第3期155-161,共7页
The objective of this study was to prepare azithromycin(AZI)sustained-release products in order to allow for a high dose to be administered,reduce gastrointestinal side-effects and increase the compliance of patients.... The objective of this study was to prepare azithromycin(AZI)sustained-release products in order to allow for a high dose to be administered,reduce gastrointestinal side-effects and increase the compliance of patients.AZI sustained-release tablets with different release performance(F-I:T_(100%)=3 h and F-II:T_(100%)=8 h in pH 6.0 phosphate buffer)were successfully prepared by wet granulation.The in vitro release rate and drug release mechanism were studied.The release rate of F-Iwas affected by dissolutionmedia with different pH,but not for F-II.HixsoneCrowellmodel was the best regression fitting model for F-I and F-II.Additionally,F-I and F-II both belonged to non-Fick diffusion.Oral pharmacokinetics of the two tablets and one AZI dispersible tablet as reference were studied in six healthy beagle dogs after oral administration.Compared with the reference,the C_(max) of F-I and F-II were decreased,and the T_(max) were prolonged,in that case which meet the requirement of sustained-release tablets.The relative bioavailability of F-I and F-II were 79.12%and 64.09%.T-test ofAUC_(0-144),and AUC_(0-∞) for F-I and F-II indicated there was no significant difference between F-I and F-II.These mean that the extended release rate did not induce different pharmacokinetics in vivo. 展开更多
关键词 AZITHROMYCIN sustained-release tablet PHARMACOKINETICS UPLC-MS-MS
下载PDF
Development and Optimization of Venlafaxine Hydrochloride Sustained Release Triple Layer Tablets Adopting Quality by Design Approach
6
作者 Shital Bhavin Butani 《Pharmacology & Pharmacy》 2013年第3期9-16,共8页
Purpose:Venlafaxine hydrochloride sustained release formulation increases patient compliance by reducing frequency of administration and it also reduces side effects like nausea and vomiting. Hence the objective of pr... Purpose:Venlafaxine hydrochloride sustained release formulation increases patient compliance by reducing frequency of administration and it also reduces side effects like nausea and vomiting. Hence the objective of present investigation was to develop triple layer sustained release tablets of venlafaxine HCl using xanthan gum or polyethylene oxide. Methods:The venlafaxine HCl 150 mg sustained release tablets were prepared by wet granulation technique where drug was incorporated in middle layer with part of polymer. The barrier layers were composed of remaining polymer and other excipients. The granules and tablets were characterised. Optimized batches were also tested for drug release at different pH and in presence of ethanol, for kinetics of drug release and for water uptake/swelling. Results: Preliminary trials of monolayer tablet showed burst release due to high dose and solubility of venlafaxine HCl and hence triple layer tablets were developed. Granules of middle layer exhibited good flow properties. The comparative drug release to Effexor? XR capsule 150 mg could be achieved by modulating the concentration of polymer and diluents in middle layer as well as in barrier layers. Higher amount of polyethylene oxide was required as compared to xanthan gum which may be due to high water uptake and poor gel strength of polyethylene oxide. The optimized formulations showed pH independent drug release as well as ethanol had no effect on drug release. Effexor? XR capsule and optimized batches followed Weibull kinetics for drug release. The radar diagrams showed the comparable drug release to innovator in both the optimized formulations but point to point correlation was observed in batch with xanthan gum. Conclusion: The layered matrix tablets formulated successfully using hydrophilic polymers, xanthan gum or polyethylene oxide, to sustain the release of highly soluble drug like venlafaxine HCl. 展开更多
关键词 venlafaxine HCL POLYETHYLENE Oxide XANTHAN Gum TRIPLE Layered tabletS
下载PDF
Clinical observation of Baitou Weng Decoction combined with mesalazine sustained-release tablets in treating heat-toxic and smoldering ulcerative colitis
7
作者 Qian-Zhang Ma Yun Li Yuan-Quan Ding 《Journal of Hainan Medical University》 2019年第12期37-42,共6页
Objective:To observe the clinical efficacy of Baitou Weng Decoction combined with mesalazine sustained-release tablets in the treatment of ulcerative colitis with febrile heat and its effect on immune function and ser... Objective:To observe the clinical efficacy of Baitou Weng Decoction combined with mesalazine sustained-release tablets in the treatment of ulcerative colitis with febrile heat and its effect on immune function and serum inflammatory factors.Methods: A total of 84 patients with ulcerative colitis were randomly divided into control group and treatment group, with 42 cases in each group. The control group was given mesalazine sustained-release tablets orally, while the treatment group was given Baitou Weng Decoction and mesalazine sustained-release tablets orally. The treatment period was 30 days and the patients were followed up for 3 months. After treatment, the clinical efficacy, quality of life, immune function and serum inflammatory factors of the two groups were observed.Results: The effective rate of treatment group (90.47%) was higher than that of control group (73.81%) (P<0.05);compared with before treatment, the scores of inflammatory bowel disease quality of life questionnaire scale in both groups were significantly improved (P<0.05), and the difference between the two groups was significant (P<0.05);after treatment, the plasma CD4+/CD8+ ratio and NK+ levels in both groups were significantly higher than those before treatment (P<0.05), and the treatment group was changed. The serum levels of tumor necrosis factor-α, interleukin-17 and interleukin-23 were significantly decreased in both groups after treatment (P<0.05), and the improvement was more significant in the treatment group (P<0.05). No significant adverse reactions were observed in the treatment group.Conclusions: Modified Baitou Weng Decoction combined with mesalazine in the treatment of heat-toxic and incandescent ulcerative colitis can significantly improve the clinical efficacy, improve the quality of life of patients, effectively regulate the expression level of serum inflammatory factors in ulcerative colitis patients, promote the recovery of patients' immune function, and have high drug safety. 展开更多
关键词 Baitou WENG DECOCTION MESALAZINE sustained-release tablets Hot toxicity ULCERATIVE colitis Immune function Serum inflammatory factor
下载PDF
Clinical observation on treatment of cancer pain with TCM oriented drugs combined with oxycodone sustained-release tablets and nimesulide sustained-release tablets
8
作者 Feng-Jiao He Ke-Xiong Li +2 位作者 Pu-Hua Zeng Hai-Yan Yi Xiao-Lan Jian 《TMR Cancer》 2018年第4期118-123,共6页
Objective: To study the effect of the transdermal preparation of traditional Chinese medicine in treating cancer pain. Methods: From October 2016 to January 2018, 126 patients with cancer pain were enrolled and divi... Objective: To study the effect of the transdermal preparation of traditional Chinese medicine in treating cancer pain. Methods: From October 2016 to January 2018, 126 patients with cancer pain were enrolled and divided into 4 groups, 39 patients in group A (directed TCM permeation), 26 patients in group B (oxycodone sustained-release tablets), 32 patients in group C (Chinese medicine directed drug penetration + oxycodone sustained-release tablets), and 29 patients group D (Chinese medicine directed drug penetration + oxycodone sustained-release tablets + nimesulide sustained release tablets), according to KPS scores. Results: Transdermal preparations of traditional Chinese medicine can significantly alleviate cancer pain. For the treatment of moderate to severe cancer pain, the Chinese medicine transdermal preparation can reduce the dosage of oxycodone sustained-release tablets. At the same time, the patient's KPS and NRS scores were significantly reduced. Moreover, the transdermal preparation of traditional Chinese medicine has a better therapeutic effect on visceral pain. Conclusion: The traditional Chinese medicine tra_nsdermal preparation combined with western medicine for the treatment of cancer pain may be a new method for the treatment of cancer pain. 展开更多
关键词 Chinese medicine directed drug Oxycodone sustained-release tablets Cancer pain Clinical efficacy
下载PDF
Simultaneous Analysis of Indapamide and Related Impurities in Sustained-Release Tablets by a Single-Run HPLC-PDA Method
9
作者 YAO Wu ZHOU Shiwen CHENG Qiongru 《Wuhan University Journal of Natural Sciences》 CAS CSCD 2023年第4期333-340,共8页
The contents of indapamide and related impurities in generic indapamide sustained-release tablets were simultaneously detected by a single-run high performance liquid chromatography equipped with photodiode array dete... The contents of indapamide and related impurities in generic indapamide sustained-release tablets were simultaneously detected by a single-run high performance liquid chromatography equipped with photodiode array detector(HPLC-PDA)method for the quality control in this paper.The results showed the method had a good selectivity and was validated through linearity,limits of detection and quantification,recovery,and precision.The linear ranges of indapamide,2-methyl-1-nitroso-2,3-dihydro-1H-indole(impurity A,ImA),4-chloro-N-(2-methyl-1H-indol-1-yl)-3-sulphamoyl-benzamide(impurity B,ImB)and 4-chloro-3-sulfamoylbenzoic acid(impurity 1,Im1)were 0.028-1.80μg/mL(R=0.99995),0.060-1.20μg/mL(R=0.9996),0.0324-1.20μg/mL(R=0.99985)and 0.060-1.20μg/mL(R=0.9997)with detection limits of 0.0093,0.012,0.012 and 0.006μg/mL,respectively.ImA and Im1 were not detectable in the generic drug.The content of indapamide was 96.7%of the labeled amount with a relative standard deviation(RSD)of 1.30%,and the percentage of ImB relative to the labeled amounts of indapamide was 0.106%with an RSD of 1.82%.The content of other unspecified impurities all met the reference quality standards.The results provided references for the quality control and the quality standard study of generic indapamide sustained-release tablets. 展开更多
关键词 INDAPAMIDE related impurity sustained-release tablets high performance liquid chromatography equipped with photodiode array detector(HPLC-PDA)
原文传递
Qualitative and quantitative analysis of HPLC fingerprint of Wuji gastric floating sustained-release tablets 被引量:1
10
作者 陈中芬 刘文 +2 位作者 陈大业 施晓伟 王群 《Journal of Chinese Pharmaceutical Sciences》 CAS CSCD 2015年第5期310-317,共8页
A qualitative and quantitative test method of fingerprint of Wuji gastric floating sustained-release tablets was established. High performance liquid chromatography (HPLC) was adopted, using Agilent ZORBAX SB-C18 co... A qualitative and quantitative test method of fingerprint of Wuji gastric floating sustained-release tablets was established. High performance liquid chromatography (HPLC) was adopted, using Agilent ZORBAX SB-C18 column (250 mm×4.6 mm, 5 μm) as the chromatographic column, and acetonitrile-0.05 mol/L potassium dihydrogen phosphate solution as the mobile phase in a gradient elution with the flow rate of 1.0 mL/min. Sample solution (10 μL) was injected and was tested at the wavelength of 225 nm for 75 min at the column temperature of 30 ℃, Fingerprint similarity software (2004A version) was used to conduct data analysis. A total of 11 batches of Wuji gastric floating sustained-release tablets were tested and analyzed with HPLC fingerprint. Seventeen common peaks were found and the similarity of the 11 batches of agents was greater than 0.9, indicating that the production process of the agent is stable and feasible. The method is operable and could effectively control the quality of Wuji gastric floating sustained-release tablets. 展开更多
关键词 FINGERPRINT HPLC Wuji gastric floating sustained-release tablets
原文传递
分析舒肝解郁胶囊配合文拉法辛片治疗老年抑郁症的临床效果 被引量:1
11
作者 安静 《罕少疾病杂志》 2023年第4期84-85,共2页
目的分析舒肝解郁胶囊配合文拉法辛片对老年抑郁症患者的效果。方法择选在本院诊治的40例老年抑郁症患者(2020年5月至2021年9月),根据随机数表法进行分组(对照组,20例,行文拉法辛片治疗;观察组,20例,行文拉法辛片+舒肝解郁胶囊治疗)。... 目的分析舒肝解郁胶囊配合文拉法辛片对老年抑郁症患者的效果。方法择选在本院诊治的40例老年抑郁症患者(2020年5月至2021年9月),根据随机数表法进行分组(对照组,20例,行文拉法辛片治疗;观察组,20例,行文拉法辛片+舒肝解郁胶囊治疗)。比较两组患者心理状态、不良反应发生率以及临床疗效。结果治疗后,观察组心理状态评分相比对照组较低(P<0.05);观察组与对照组的不良反应发生率对比(P>0.05);观察组临床疗效相比对照组较高(P<0.05)。结论经舒肝解郁胶囊配合文拉法辛片治疗后,效果显著,可有效调节患者的心理状态,缓解抑郁症状,建议在临床推广应用。 展开更多
关键词 舒肝解郁胶囊 文拉法辛片 老年抑郁症 心理状态
下载PDF
氢溴酸西酞普兰片联合文拉法辛缓释片治疗精神分裂症伴抑郁症状患者的效果及对社会功能的影响
12
作者 翟丽芬 彭冰冰 《临床医学研究与实践》 2023年第11期34-37,共4页
目的探究氢溴酸西酞普兰片联合文拉法辛缓释片治疗精神分裂症伴抑郁症状患者的效果及对社会功能的影响。方法选取2020年1月至2021年12月于本院确诊为精神分裂症伴抑郁症状的80例患者作为研究对象,依据随机数字表法将其分为对照组和研究... 目的探究氢溴酸西酞普兰片联合文拉法辛缓释片治疗精神分裂症伴抑郁症状患者的效果及对社会功能的影响。方法选取2020年1月至2021年12月于本院确诊为精神分裂症伴抑郁症状的80例患者作为研究对象,依据随机数字表法将其分为对照组和研究组,各40例。对照组给予盐酸文拉法辛缓释片治疗,研究组在对照组基础上给予氢溴酸西酞普兰片治疗。比较两组的治疗效果、个人和社会功能量表(PSP)、汉密尔顿抑郁量表(HAMD)、自尊量表(SES)、阳性症状量表(SAPS)、阴性症状量表(SANS)评分、神经功能指标及不良反应发生情况。结果研究组的治疗总有效率为95.00%,高于对照组的75.00%,差异具有统计学意义(P<0.05)。治疗前,两组的PSP、HAMD及SES评分比较,差异无统计学意义(P>0.05);治疗后,两组的PSP、SES评分均升高,HAMD评分均降低,且研究组优于对照组,差异具有统计学意义(P<0.05)。治疗前,两组的SAPS、SANS评分比较,差异无统计学意义(P>0.05);治疗后,两组的SAPS、SANS评分均降低,且研究组低于对照组,差异具有统计学意义(P<0.05)。治疗前,两组的胶质细胞源性神经营养因子(GDNF)、神经元特异性烯醇化酶(NSE)及中枢神经特异蛋白(S100β)水平比较,差异无统计学意义(P>0.05);治疗后,两组的GDNF水平均升高,NSE、S100β水平均降低,且研究组优于对照组,差异具有统计学意义(P<0.05)。两组的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论氢溴酸西酞普兰片联合文拉法辛缓释片治疗精神分裂症伴抑郁症状患者的效果较好,可改善抑郁症状,提高社会功能,值得临床应用。 展开更多
关键词 氢溴酸西酞普兰片 文拉法辛缓释片 精神分裂症 抑郁症状 社会功能
下载PDF
阿立哌唑片剂联合文拉法辛缓释片对精神分裂症阴性症状的治疗效果观察
13
作者 杨丽娜 时亚丽 《智慧健康》 2023年第3期56-59,共4页
目的探究精神分裂症阴性症状患者使用阿立哌唑片剂联合文拉法辛缓释片的治疗效果。方法选择80例精神分裂症阴性症状患者(2018年10月-2020年10月)作为研究对象,采用随机数字表法分组,服用拉力哌唑片治疗的40例组成对照组,观察组在对照组... 目的探究精神分裂症阴性症状患者使用阿立哌唑片剂联合文拉法辛缓释片的治疗效果。方法选择80例精神分裂症阴性症状患者(2018年10月-2020年10月)作为研究对象,采用随机数字表法分组,服用拉力哌唑片治疗的40例组成对照组,观察组在对照组基础上加用文拉法辛缓释片。比较两组临床疗效、PANSS评分(阳性与阴性症状量表),同时对比不良反应概率、比较生活质量变化。结果治疗有效率两组比较观察组更高,差异有统计学意义(P<0.05);观察组治疗后PANSS评分相比于治疗前改善幅度明显大于对照组,差异有统计学意义(P<0.05);不良反应概率组间比较差异不显著,差异无统计学意义(P>0.05)。观察组SF-36评分增加幅度相比于对照组显著更大,差异有统计学意义(P<0.05)。结论精神分裂症阴性症状患者给予阿立哌唑片剂联合文拉法辛缓释片治疗的效果优于单纯使用阿立哌唑片,患者症状改善效果良好,并且不会增加用药不良反应,患者生活质量得到显著提升,治疗价值高,可临床广泛应用。 展开更多
关键词 精神分裂症 阴性症状 阿立哌唑片 文拉法辛缓释片 疗效 并发症 生活质量
下载PDF
文拉法辛及黛力新治疗部队官兵焦虑抑郁障碍的疗效对比 被引量:9
14
作者 周红宇 朱高莉 +2 位作者 周国华 陈叶青 冷明芳 《实用药物与临床》 CAS 2013年第5期376-378,共3页
目的观察文拉法辛及黛力新治疗部队官兵焦虑抑郁障碍的效果。方法收集2008年1月至2012年6月因消化道症状为主在我院消化科住院的部队患者,经排除器质性疾病并采用汉密尔顿焦虑抑郁量表评分,明确诊断为焦虑抑郁障碍者67例,随机分为文拉... 目的观察文拉法辛及黛力新治疗部队官兵焦虑抑郁障碍的效果。方法收集2008年1月至2012年6月因消化道症状为主在我院消化科住院的部队患者,经排除器质性疾病并采用汉密尔顿焦虑抑郁量表评分,明确诊断为焦虑抑郁障碍者67例,随机分为文拉法辛组(35例)及黛力新组(32例),治疗后2周、3个月、6个月观察患者初始症状,记录焦虑抑郁量表评分。结果治疗2周、3个月、6个月时,两组焦虑抑郁量表评分均降低(P<0.05);治疗6个月时,文拉法辛组低于黛力新组(P<0.05)。文拉法辛组常见的不良反应为恶心、头昏、便秘等,2周后基本消失;黛力新组无明显不良反应。治疗6个月时文拉法辛组有效率高于黛力新组(P<0.05)。结论文拉法辛及黛力新治疗部队焦虑抑郁障碍患者均有明显效果,早期差异无统计学意义,但长期随访结果显示,文拉法辛效果更稳定,其疗效优于黛力新。 展开更多
关键词 焦虑 抑郁 文拉法新 黛力新
下载PDF
盐酸文拉法辛凝胶骨架片的制备及体外释药特性研究 被引量:3
15
作者 贺周扬 谭银合 +3 位作者 张好好 付寒 房秋雨 吴传斌 《广东药学院学报》 CAS 2012年第2期111-116,共6页
目的制备盐酸文拉法辛(VH)亲水凝胶骨架片,考察处方、工艺对其体外释药行为的影响,并对其释药机理进行初步分析。方法以羟丙基甲基纤维素(HPMC)为基本骨架材料,羧甲基纤维素钠(CMC-Na)为阻滞剂,采用湿法制粒制备凝胶骨架片,通过单因素... 目的制备盐酸文拉法辛(VH)亲水凝胶骨架片,考察处方、工艺对其体外释药行为的影响,并对其释药机理进行初步分析。方法以羟丙基甲基纤维素(HPMC)为基本骨架材料,羧甲基纤维素钠(CMC-Na)为阻滞剂,采用湿法制粒制备凝胶骨架片,通过单因素试验筛选辅料种类,利用正交设计试验优化处方,建立释放度测定方法,并通过不同方程拟合释放曲线。结果盐酸文拉法辛缓释片体外释药符合一级释药特征,药物释放主要是通过Fick扩散完成。HPMC用量和黏度、阻滞剂用量对释放速率有显著影响,填充剂、制粒方法和压片压力对释放速率的影响不显著。结论以HPMC K100M和CMC-Na为骨架材料,制备的盐酸文拉法辛缓释片具有良好的缓释效果。 展开更多
关键词 盐酸文拉法辛 羟丙基甲基纤维素 羧甲基纤维素钠 骨架片
下载PDF
包衣处方对盐酸文拉法辛微孔渗透泵型控释片体外释药的影响 被引量:4
16
作者 金玲宇 张宇 +2 位作者 韩飞 焦成美 李三鸣 《沈阳药科大学学报》 CAS CSCD 北大核心 2008年第8期593-597,共5页
目的考察包衣处方对盐酸文拉法辛口服微孔渗透泵控释片体外释药的影响,并优选最佳包衣处方。方法考察聚乙二醇400(PEG400)的用量、包衣增量、邻苯二甲酸二丁酯(DBP)的种类和用量4个因素对释放的影响,并通过正交设计优化包衣处方。结果... 目的考察包衣处方对盐酸文拉法辛口服微孔渗透泵控释片体外释药的影响,并优选最佳包衣处方。方法考察聚乙二醇400(PEG400)的用量、包衣增量、邻苯二甲酸二丁酯(DBP)的种类和用量4个因素对释放的影响,并通过正交设计优化包衣处方。结果盐酸文拉法辛微孔渗透泵控释片的体外释药符合零级释放规律,释药速率受致孔剂、增塑剂、衣膜厚度的影响均较大。结论通过对包衣处方的优化,盐酸文拉法辛口服微孔渗透泵控释片能够恒速释药。 展开更多
关键词 盐酸文拉法辛 微孔渗透泵片 正交设计 零级释放
下载PDF
文拉法辛缓释片与西酞普兰、阿米替林治疗抑郁症的对照研究 被引量:6
17
作者 刘文庭 杨云霞 +3 位作者 赵洁 徐开营 刘秋英 刘溪琨 《中国实用神经疾病杂志》 2012年第24期29-31,共3页
目的比较文拉法辛缓释片与西酞普兰、阿米替林治疗抑郁症的疗效、不良反应。方法将120例抑郁症患者随机分为3组,分别给于文拉法辛缓释片(博乐新)、西酞普兰、阿米替林治疗4周。采用汉米尔顿抑郁量表(HAMD)、不良反应量表(TESS)在治疗前... 目的比较文拉法辛缓释片与西酞普兰、阿米替林治疗抑郁症的疗效、不良反应。方法将120例抑郁症患者随机分为3组,分别给于文拉法辛缓释片(博乐新)、西酞普兰、阿米替林治疗4周。采用汉米尔顿抑郁量表(HAMD)、不良反应量表(TESS)在治疗前和治疗第1、2、4周末分别评定疗效、不良反应。结果文拉法辛缓释片组在第1周末即显效,HAMD评分与治疗前比较差异有统计学意义,与另2组比较差异亦有统计学意义(P<0.05,P<0.01);其余2组与治疗前比较差异无统计学意义(P>0.05)。文拉法辛缓释片组第2周末与治疗前比较差异有统计学意义(P<0.01),3组间比较差异有统计学意义(P<0.05)。至第4周末3组与治疗前比较差异均有统计学意义(P<0.01),但3组间比较差异无统计学意义(P>0.05)。阿米替林组锥体外系及抗胆碱能不良反应最高,消化系统和精神、神经系统不良反应西酞普兰组最高。结论文拉法辛缓释片治疗抑郁症与阿米替林及西酞普兰比较起效较快,不良反应较少。 展开更多
关键词 抑郁症 文拉法辛缓释片 西酞普兰 阿米替林
下载PDF
文拉法辛缓释片与米安合林治疗老年抑郁症对照研究 被引量:11
18
作者 贡永宁 郭平 《临床心身疾病杂志》 CAS 2011年第1期21-22,共2页
目的探讨文拉法辛缓释片与米安舍林治疗老年抑郁症的临床疗效及安全性。方法将78例老年抑郁症患者随机分为两组,每组38例,研究组晨口服文拉法辛缓释片治疗,对照组每晚口服米安舍林治疗,观察8周。于治疗前及治疗2周、4周、6周、8周... 目的探讨文拉法辛缓释片与米安舍林治疗老年抑郁症的临床疗效及安全性。方法将78例老年抑郁症患者随机分为两组,每组38例,研究组晨口服文拉法辛缓释片治疗,对照组每晚口服米安舍林治疗,观察8周。于治疗前及治疗2周、4周、6周、8周末采用汉密顿抑郁量表评定临床疗效,副反应量表评定不良反应。结果研究组治疗2周末起,对照组治疗4周末起,汉密顿抑郁量表总分均较治疗前有显著下降(P〈0.01);但研究组治疗2周末较对照组下降更显著(P〈0.05),其他时段评分均无显著性差异(P〉0.05);副反应量表各时段评分研究组均显著低于对照组(P〈0.05);治疗8周末两组总有效率均为89.47%。结论文拉法辛缓释片治疗老年抑郁症疗效显著,且与米安舍林疗效相当,但文拉法辛缓释片较起效更快,安全性更高,依从性更好。 展开更多
关键词 老年抑郁症 文拉法辛缓释片 米安舍林 汉密顿抑郁量表 副反应量表
下载PDF
阿立哌唑片联合文拉法辛缓释片治疗伴抑郁症状精神分裂症的疗效观察 被引量:6
19
作者 米莉 罗明 《中国医学前沿杂志(电子版)》 2014年第7期154-156,共3页
目的探讨采用阿立哌唑片联合文拉法辛缓释片治疗伴有抑郁症状的精神分裂症患者的临床疗效。方法选取患有精神分裂症且经汉密尔顿抑郁量表(HAMD)评估后确诊为伴抑郁症状的70例患者,随机均分为对照组与治疗组,对照组患者采用阿立哌唑片进... 目的探讨采用阿立哌唑片联合文拉法辛缓释片治疗伴有抑郁症状的精神分裂症患者的临床疗效。方法选取患有精神分裂症且经汉密尔顿抑郁量表(HAMD)评估后确诊为伴抑郁症状的70例患者,随机均分为对照组与治疗组,对照组患者采用阿立哌唑片进行治疗,治疗组患者采用阿立哌唑片与文拉法辛缓释片进行联合治疗,8周为1个疗程,对两组患者1个疗程后的临床疗效、HAMD评分、不良反应量表(TESS)评分以及不良反应情况进行对照比较。结果开始治疗后第2、4、8周时对两组患者进行HAMD评分,结果显示治疗组患者评分明显低于对照组,差异具有显著性(P<0.05);治疗组临床疗效明显优于对照组,差异具有显著性(P<0.05);治疗组患者TESS评分明显低于对照组,差异具有显著性(P<0.05)。结论采用阿立哌唑片联合文拉法辛缓释片治疗精神分裂症伴抑郁症状,临床疗效显著,患者耐受性好,见效较快,具有临床应用及推广价值。 展开更多
关键词 阿立哌唑片 文拉法辛缓释片 精神分裂症 抑郁症状
下载PDF
盐酸文拉法辛微孔型渗透泵片的制备工艺研究 被引量:1
20
作者 刘辉 漆正林 +1 位作者 刘宏 汤韧 《医药导报》 CAS 2009年第10期1331-1334,共4页
目的制备具有零级释药特征的盐酸文拉法辛微孔型渗透泵片。方法以累积释药百分率为指标,采用单因素法考察片芯组成和衣膜处方对制剂释药行为的影响。结果优化后的盐酸文拉法辛微孔型渗透泵片遵从以渗透压作为主要释药动力的零级模型,体... 目的制备具有零级释药特征的盐酸文拉法辛微孔型渗透泵片。方法以累积释药百分率为指标,采用单因素法考察片芯组成和衣膜处方对制剂释药行为的影响。结果优化后的盐酸文拉法辛微孔型渗透泵片遵从以渗透压作为主要释药动力的零级模型,体外释药方程为:Q=7.454 3t+2.877 1,r=0.998 3。结论基于渗透压释药机制的盐酸文拉法辛微孔型渗透泵片理论可行,结果可控,有利于渗透泵控释制剂的产业化推广。 展开更多
关键词 文拉法辛 盐酸 渗透泵片 微孔型 工艺
下载PDF
上一页 1 2 5 下一页 到第
使用帮助 返回顶部